Azioni Advanced Accelerator Application SA(ADR)

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
-	-

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications	03/12/18
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer	12/02/18
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer	01/02/18
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors	26/01/18
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer	22/01/18

Dirigenti	Titolo	Età	Da
Caio Kugelmas DFI	Director of Finance/CFO	-	-
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	01/10/19
Ute Simon CTO	Chief Tech/Sci/R&D Officer	-	01/04/20

Amministratori	Titolo	Età	Da
Frédéric Collet BRD	Director/Board Member	-	01/01/18
Jessica Toepfer BRD	Director/Board Member	-	01/01/18
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	01/10/19

Settore

	Variaz. 1 gen.	Capi.
MERCK KGAA	+5,31%	70,44 Mrd
KYOWA KIRIN CO. LTD.	+10,97%	8,94 Mrd
SK BIOPHARMACEUTICALS CO., LTD.	-16,83%	4,75 Mrd
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43,48%	4,5 Mrd
YUHAN CORPORATION	+3,20%	3,85 Mrd
INDIVIOR PLC	+18,82%	2,38 Mrd
BETTA PHARMACEUTICALS CO., LTD.	-21,36%	2,34 Mrd
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29,67%	2,2 Mrd
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8,38%	1,96 Mrd